EUVIMEDEUVIMED entdecken
Crossref

Bioengineered bacterial extracellular vesicles for targeted delivery of an osteoclastogenesis-inhibitory peptide to alleviate osteoporosis

Xiangxiang Kong, Han Liu, Sumeng Chen, Zhinan Liu, Qin Chen, Xiang Li, Honggang Hu, Jiacan Su, Yejiao Shi

Journal of Controlled Release · 2025-06 · 382 · 113751

DOI: 10.1016/j.jconrel.2025.113751 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2025-06. Verfasst von Xiangxiang Kong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Medicine, Shanghai University, Shanghai 200444, China; National Center for Translational Medicine (Shanghai) SHU Branch, S…. Hauptthemen laut MEDLINE: Extracellular Vesicles, Osteoporosis, Escherichia coli, Peptides. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China, Natural Science Foundation of Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoporosis (OP) is a systemic skeletal disease commonly found in women after 55 years old and men after 65 years old. With the worldwide aging of population, its prevalence rate is increasing rapidly, bringing huge financial burdens to all countries. As a potential alternative to the conventional OP therapeutics with limited efficacies and side effects, a linear peptide FRATtide capable of binding with phosphorylated GSK3β has been discovered by us to inhibit osteoclastogenesis thus reduce bone loss. While its poor proteolytic stability and osteoclast targetability hinder its effective in vivo treatment. As such, bacterial extracellular vesicles secreted by the rationally recombinant probiotics Escherichia coli Nissle 1917 that express pre-osteoclast fusion protein DC-STAMP (BEV-DCS) are engineered and exploited as delivery vehicles. The BEV-DCS not only protect FRAT from enzymatic degradation but also enable its targeted intracellular delivery into pre-osteoclasts. On the ovariectomy mouse model, the FRAT encapsulated BEV-DCS (FRAT@BEV-DCS) exhibit remarkable bone targeting capacity and osteoporosis ameliorating efficacy without any obvious toxicity. These results reveal the great potential of FRAT@BEV-DCS as a novel therapeutic option for the effective and safe OP treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesOsteoporosisEscherichia coliPeptidesAnimalsFemaleMiceOsteoclastsOsteogenesisHumansMembrane ProteinsDrug Delivery SystemsMice, Inbred C57BLRAW 264.7 Cells

Stichwörter der Autor:innen

Bacterial extracellular vesicleBone targetingIntracellular deliveryOsteoporosisStability

Substanzen

Membrane ProteinsPeptides

Autor:innen und Institutionen

  • Institute of Translational Medicine, Shanghai University, Shanghai 200444, China; National Center for Translational Medicine (Shanghai) SHU Branch, Shanghai University, Shanghai 200444, China; MedEng-X Insititutes, Shan…
  • School of Life Sciences, Shanghai University, Shanghai 200444, China.
  • School of Pharmacy, Naval Medical University, Shanghai 200433, China.
  • School of Medicine, Shanghai University, Shanghai 200444, China; Shanghai Integration and Innovation Center of Marine Medical Engineering, Shanghai 200444, China. Electronic address: hhu66@shu.edu.cn.

Förderung

  • Natural Science Foundation of Jiangsu Province
  • National Natural Science Foundation of China
  • Natural Science Foundation of Fujian Province
  • Innovative Research Group Project of the National Natural Science Foundation of China

Zitieren

APA

Kong, X., Liu, H., Chen, S., Liu, Z., Chen, Q., Li, X., Hu, H., Su, J., & Shi, Y. (2025). Bioengineered bacterial extracellular vesicles for targeted delivery of an osteoclastogenesis-inhibitory peptide to alleviate osteoporosis. Journal of Controlled Release, 382, 113751. https://doi.org/10.1016/j.jconrel.2025.113751

Vancouver

Kong X, Liu H, Chen S, Liu Z, Chen Q, Li X, et al. Bioengineered bacterial extracellular vesicles for targeted delivery of an osteoclastogenesis-inhibitory peptide to alleviate osteoporosis. Journal of Controlled Release. 2025;382:113751. doi:10.1016/j.jconrel.2025.113751

BibTeX
@article{Kong2025,
  author = {Kong, Xiangxiang and Liu, Han and Chen, Sumeng and Liu, Zhinan and Chen, Qin and Li, Xiang and Hu, Honggang and Su, Jiacan and Shi, Yejiao},
  title = {Bioengineered bacterial extracellular vesicles for targeted delivery of an osteoclastogenesis-inhibitory peptide to alleviate osteoporosis},
  journal = {Journal of Controlled Release},
  year = {2025},
  volume = {382},
  pages = {113751},
  doi = {10.1016/j.jconrel.2025.113751}
}
Kostenlos starten →